Receiving a platform technology designation from the FDA is a tremendous milestone for our development team and Krystal, both as recognition of the reproducibility and scalability of our HSV-1 gene ...
TipRanks on MSN
Krystal Biotech’s Promising Study on KB801 for Neurotrophic Keratitis: Market Implications
Krystal Biotech, Inc. (($KRYS)) announced an update on their ongoing clinical study. Krystal Biotech, Inc. is conducting a clinical study titled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback